Welcome to our dedicated page for G1 Therapeutics news (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics stock.
G1 Therapeutics, Inc. (Nasdaq: GTHX) is a commercial-stage oncology biopharmaceutical company committed to developing next-generation therapies to improve the lives of cancer patients. The company is based in Research Triangle Park, N.C., and leverages its proprietary kinase drug discovery platform to advance a pipeline of innovative compounds. G1's flagship product, COSELA® (trilaciclib), has been approved by the FDA to decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC).
In addition to COSELA, G1 Therapeutics is actively developing and evaluating trilaciclib in combination with other anti-cancer therapies. One notable project is the global, multi-center, randomized, placebo-controlled Phase 3 trial known as PRESERVE 2, which investigates trilaciclib in patients with metastatic triple-negative breast cancer (mTNBC). Preliminary results have shown promising survival benefits, indicating trilaciclib’s potential to protect bone marrow and enhance patient outcomes during cytotoxic therapy.
The company also engages in strategic partnerships to broaden its impact. For instance, G1 Therapeutics has entered agreements with companies like Pepper Bio and Jupiter Bioventures to advance the clinical development and commercialization of lerociclib, another promising CDK4/6 inhibitor. These collaborations aim to explore lerociclib's efficacy in treating various cancers, including HCC and radioprotection uses.
On the financial front, G1 Therapeutics reported revenues of $82.5 million for the full year 2023, reflecting significant growth from $51.3 million in the previous year. The company's ongoing commitment to innovation and strategic collaborations underscores its role as a key player in oncology therapeutics.
For more information, visit G1 Therapeutics and follow them on Twitter and LinkedIn.
G1 Therapeutics, Inc. (GTHX) announced a webcast and conference call scheduled for May 3, 2023, at 8:30 a.m. ET, to provide a financial and corporate update for Q1 2023. The live event will discuss the company’s progress in developing COSELA® (trilaciclib), its first commercial product, and ongoing clinical trials across various solid tumors, including breast, lung, and bladder cancers. Participants are encouraged to register online to receive dial-in details, and a recorded version of the webcast will be available for 90 days post-event on the company's website. G1 Therapeutics continues to focus on advancing therapies that enhance patient outcomes in oncology.
FAQ
What is the current stock price of G1 Therapeutics (GTHX)?
What is the market cap of G1 Therapeutics (GTHX)?
What does G1 Therapeutics, Inc. specialize in?
What is COSELA® (trilaciclib)?
What is the PRESERVE 2 trial?
Where is G1 Therapeutics, Inc. located?
Who are G1 Therapeutics' key partners?
What recent financial achievements has G1 Therapeutics reported?
What is lerociclib?
How can I get more information about G1 Therapeutics?
What types of cancer are G1 Therapeutics’ therapies targeting?
What are G1 Therapeutics’ future goals?
